Ben-Gurion University of the Negev

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

Retrieved on: 
Monday, November 29, 2021
Patient, Private Securities Litigation Reform Act, Risk, European, Company, Neoplasm, Human, Research and development, Form, Ben-Gurion University of the Negev, Kidney, Breast, Organizational behavior, SEC, Goal, Freezing, Research, Marketing, Development, FDA, NASDAQ, TASE, Human resources, Medical imaging, Management

(NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources.

Key Points: 
  • (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources.
  • Mrs. Nir Dotan has over two decades of experience in human resources and organizational management.
  • "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chief Executive Officer of IceCure.
  • Mrs. Nir Dotan was previously Vice President of Human Resources at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, and previously served in roles handling recruitment and marketing.

21st Century Dental Welcomes Periodontist Dr. Alon Shalev to the Staff

Retrieved on: 
Friday, November 19, 2021
Patient, Dental, Degenerative disease, Dentist, Outline of health sciences, Century Dental College, Poinachy, American Academy of Periodontology, Dental care, University, Cosmetic dentistry, Periodontology, Publishing, Micro, Ben-Gurion University of the Negev, Lithuanian University of Health Sciences, American Academy, Dentistry

IRVING, Texas, Nov. 19, 2021 /PRNewswire/ -- 21st Century Dental has recently welcomed Dr. Alon Shalev to their staff to serve as a periodontist.

Key Points: 
  • IRVING, Texas, Nov. 19, 2021 /PRNewswire/ -- 21st Century Dental has recently welcomed Dr. Alon Shalev to their staff to serve as a periodontist.
  • The services that Dr. Shalev offers at 21st Century Dental include:
    Implant Placement: Many dental practices have to refer their patients to specialists to have it performed.
  • As a multispecialty practice, 21st Century Dental is able to offer a team approach to dental care.
  • To learn more about Dr. Salev or the services that he offers as a periodontist, visit the 21st Century Dental website or call their office at (972) 885-3510.

Fujitsu and Ben-Gurion University Embark on Joint Research at New Center in Israel for Precise and Secure AI

Retrieved on: 
Tuesday, November 16, 2021
Learning, University, PayPal, Business, Industry, Science, BGU, Engineering, Behavior, Government, Student, Center, Dell EMC, Method, Heart, Incubator, CEO, Department, Information system, Humanities, Machine learning, Growth, Research, ICT, Software, AI, Head, Ben-Gurion University of the Negev, Entrepreneurship, Partnership, IL, Albert Katz International School for Desert Studies, Fraud, Lockheed, Solution, Faculty, Business process management, TÜBİTAK Informatics and Information Security Research Center, Deutsche Telekom, US, Social science, Outline of health sciences, Natural science, Bachelor of Engineering, Weapon, Medical device, Management

The newly-established "Fujitsu Cybersecurity Center of Excellence in Israel" (Fujitsu CCoE IL) hosts a team of approximately 20 researchers including Prof. Yuval Elovici and Prof. Asaf Shabtai.

Key Points: 
  • The newly-established "Fujitsu Cybersecurity Center of Excellence in Israel" (Fujitsu CCoE IL) hosts a team of approximately 20 researchers including Prof. Yuval Elovici and Prof. Asaf Shabtai.
  • Prof. Yuval Elovici, said, "We are excited to enhance our collaboration with Fujitsu, a world-leading information and communications technology company.
  • Together we can make systems that are based on AI more robust to attacks that focus on the AI component."
  • "This joint strategic research collaboration is a testament to Ben-Gurion University's leadership in the cybersecurity space," added Josh Peleg, CEO, BGN Technologies.

Fujitsu and Ben-Gurion University Embark on Joint Research at New Center in Israel for Precise and Secure AI

Retrieved on: 
Tuesday, November 16, 2021
University, BGU, Engineering, Behavior, Center, CEO, Department, Information system, Machine learning, Growth, Attack, Research, Software, AI, Head, Ben-Gurion University of the Negev, Partnership, Limited, IL, Solution, Cooperative Cyber Defence Centre of Excellence, TÜBİTAK Informatics and Information Security Research Center, Medical device

Vivek Mahajan,Chief Technology Officer of Fujitsu Limited commented, "We are delighted to collaborate with Ben-Gurion University, which boasts world-class software development capabilities in the security field.

Key Points: 
  • Vivek Mahajan,Chief Technology Officer of Fujitsu Limited commented, "We are delighted to collaborate with Ben-Gurion University, which boasts world-class software development capabilities in the security field.
  • Together we can make systems that are based on AI more robust to attacks that focus on the AI component."
  • "This joint strategic research collaboration is a testament to Ben-Gurion University's leadership in the cybersecurity space," added Josh Peleg, CEO, BGN Technologies.
  • As part of their new partnership, Fujitsu and BGU will focus on research that confronts these threats to make AI technologies safer and more trustworthy.

IR-Med to Become Fully Reporting SEC Company

Retrieved on: 
Friday, November 12, 2021
Compliance, Subcutaneous tissue, University, Form, Register, UCSF, Private Securities Litigation Reform Act, Artificial intelligence, Pressure, Tissue engineering, Prospectus, Merck, CEO, MBA, Doctor of Philosophy, Technology, Blood, Exercise, PCAOB, University of California, San Francisco, Sale, Ben-Gurion University of the Negev, Weizmann Institute of Science, Biotechnology, GLOBE, U.S. Securities and Exchange Commission, SEC, Registration statement, Nature, Latin honors, Physician, OTCQB, Â, Skin, OTC Markets Group, Boston, Security (finance), Medical imaging

New York, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- IR-Med, Inc. (OTCPINK: IRME), a development stage medical device company that utilizes Infra-Red (IR) light spectroscopy analysis combined with Artificial Intelligence (AI) technologies to address currently unmet medical needs, announces that the United States Securities and Exchange Commission (the "SEC") declared IR-Med's resale Registration Statement on Form S-1 (the "Registration Statement") effective on November 9, 2021. IR-Med became an SEC reporting company upon effectiveness of the Registration Statement.

Key Points: 
  • IR-Med became an SEC reporting company upon effectiveness of the Registration Statement.
  • Rather, the Registration Statement relates to the potential resale, from time to time, of securities of IR-Med by certain of its security holders.
  • IR-Med will not receive any proceeds from any sale of securities by the selling security holders pursuant to the Registration Statement.
  • Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions.

Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15

Retrieved on: 
Tuesday, November 2, 2021
KOL, Cirrhosis, MD, Research, AASLD, Diagnosis, University, Ben-Gurion University of the Negev, Disease, Association, Institute of Liver and Biliary Sciences, Lonafarnib, Global health, PALO, AM, Outline of health sciences, III, Faculty, Patient, American Association for the Study of Liver Diseases, Liver cancer, Hepatitis B virus, HBsAg, Center, McMaster Faculty of Health Sciences, Liver disease, Non-alcoholic fatty liver disease, International, Company, Transplant, Viral hepatitis, Investor relations, Eiger, Fondazione Child, American Association, Therapy, Liver failure, HDV, Coinfection, Doctor of Philosophy, University of Milan, HBV, Department, Pharmaceutical industry, Medicine, Fine chemical, Vaccine

PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.

Key Points: 
  • PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.
  • The event is scheduled to take place on Monday, November 15, 2021 from9:00-10:30 AM ETand will be simultaneously webcast.
  • The live and replayed webcast of the event will be available through the Investor Relations "Events & Presentations" section of the company's website at www.eigerbio.com .
  • His most recent project involves treatment of hepatitis Delta patients with Lonafarnib and Peginterferon Lambda.

Dr. Tal Zaks and Dr. Sheila Gujrathi Join OrbiMed

Retrieved on: 
Monday, November 1, 2021
Research, Finance, Banking, Professional Services, Biotechnology, Health, General Health, Other Science, Science, COVID-19, McKinsey & Company, Norwest Venture Partners, Drug development, Private equity, Bristol Myers Squibb, Patient, Medical education, Genentech, Sanofi, Hospital, Biomedical engineering, Growth, UCSF, Stanford University, Solution, TAL, Partner (business rank), Ben-Gurion University of the Negev, GlaxoSmithKline, Pharmaceutical industry

Tal Zaks, M.D., Ph.D., joined OrbiMed as a Venture Partner.

Key Points: 
  • Tal Zaks, M.D., Ph.D., joined OrbiMed as a Venture Partner.
  • Previously, Dr. Zaks held senior leadership positions in drug development at major pharmaceutical companies, including Sanofi and GlaxoSmithKline.
  • Sheila Gujrathi, M.D., joined OrbiMed as a Venture Advisor.
  • We are excited to welcome Tal and Sheila to the OrbiMed team, stated Carl Gordon, a Managing Partner and Head of Private Equity at OrbiMed.

Tal Zaks Joins Strategic Advisory Board at Deep Genomics

Retrieved on: 
Tuesday, October 26, 2021
Health, Technology, Other Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, RNA transfection, MD, Research, University, Genomics, LinkedIn, Gene, Industry, Tesla, SpaceX, Oncology, Â, Deep learning, Twitter, Patient, Teva Pharmaceuticals, Ben-Gurion University of the Negev, Machine learning, Jazz Pharmaceuticals, RNA, Tuskegee Veterans Administration Medical Center, Leadership, FRSC, Life, Central Waqf Council, MA, CEO, Board, Internal medicine, COVID-19, Multimedia, Program, Lists of diseases, Artificial intelligence, Temple University Hospital, Therapy, Oligonucleotide, Doctor of Philosophy, GlaxoSmithKline, Clinical Genitourinary Cancer, Associate, Genetics, AI, Medical device, Pharmaceutical industry, Tal Zaks, MD, PhD, Deep Genomics, TAL ZAKS, MD, PHD, DEEP GENOMICS

Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today.

Key Points: 
  • Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today.
  • By applying its innovative AI platform to create oligonucleotides as programmable medicines, Deep Genomics has demonstrated remarkable productivity in advancing a broad pipeline of preclinical programs, says Zaks.
  • The strategic advisory board of Deep Genomics includes Jennifer Cook of BridgeBio, Denali Therapeutics and Jazz Pharmaceuticals, and Steve Jurvetson of SpaceX and Tesla.
  • Tal Zaks is Strategic Advisor at Deep Genomics, with a focus on growing the company to take advantage of the many targets, mechanisms and molecules generated by their programmable medicines platform.

OCP Group and ICL Join Forces to Support Sustainability Programs at UM6P and BGU

Retrieved on: 
Wednesday, October 13, 2021
Men, Research, Philanthropy, Consumer, Other Education, University, Environment, Fund Raising, Education, Science, Other Consumer, Women, Other Philanthropy, Leadership, ICL Group Ltd., School of Business and Management of Technology of BSU, Government, Muhammad, Technology, Faculty, Hospitality, Climate change, Tel Aviv Stock Exchange, Industry, Solution, New, Heart, Ben-Gurion University of the Negev, Social responsibility, Growth, Venture capital, Food security, Business, Sustainability, Outline of health sciences, Social science, Knowledge, Humanities, Education, School, NYSE, Multimedia, Soil, Bromine, OCP Group, Photograph, Science, TASE, Student, Agriculture, ICL, University, CEO, BGU, Natural science, Water, Albert Katz International School for Desert Studies, OCP, Group, Research, Partnership, Management, Renewable energy, Medicine, OCP, ICL, Mohammed VI Polytechnic University, Ben-Gurion University of the Negev, OCP, ICL, MOHAMMED VI POLYTECHNIC UNIVERSITY, BEN-GURION UNIVERSITY OF THE NEGEV

OCP Group and ICL Group signed today a memorandum of understanding to offer scholarships to promote research and academic excellence through the funding of sustainability programs at Mohammed VI Polytechnic University (UM6P) and Ben-Gurion University of the Negev (BGU).

Key Points: 
  • OCP Group and ICL Group signed today a memorandum of understanding to offer scholarships to promote research and academic excellence through the funding of sustainability programs at Mohammed VI Polytechnic University (UM6P) and Ben-Gurion University of the Negev (BGU).
  • For the implementation of these activities, OCP Group will provide initial funding of $300,000 to UM6P, and ICL Group will provide a similar amount to BGU, for a total of $US 600,000.
  • Daniel Chamovitz, President of Ben-Gurion University of the Negev said, BGU and UM6P have much in common.
  • ICL shares are dually listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL).

Wave Energy Developer, Eco Wave Power, Strengthens Management - Appoints Chief Operating Officer

Retrieved on: 
Wednesday, October 13, 2021
Leadership, Organization, Ben-Gurion University of the Negev, Nasdaq, Solar Impulse, Climate change, Employment, Nasdaq First North, Economics, Engineering, Solar Impulse Foundation, FNCA, VP, European, Founder, Avi, Business administration, CEO, COO, EPC, Maintenance, United Nations, WAVE, Agency, Tissue paper, Management, Renewable energy

STOCKHOLM, Oct. 13, 2021 /PRNewswire/ -- Publicly traded wave energy developer, Eco Wave Power Global AB (publ) ("Eco Wave Power") (Nasdaq US: WAVE, Nasdaq First North: ECOWVE), announces today the appointment of Mr. Avi Waller as Chief Operating Officer for the Eco Wave Power Group.

Key Points: 
  • STOCKHOLM, Oct. 13, 2021 /PRNewswire/ -- Publicly traded wave energy developer, Eco Wave Power Global AB (publ) ("Eco Wave Power") (Nasdaq US: WAVE, Nasdaq First North: ECOWVE), announces today the appointment of Mr. Avi Waller as Chief Operating Officer for the Eco Wave Power Group.
  • Mr. Waller will begin his employment immediately and will be based in Eco Wave Power's headquarters in Tel Aviv, Israel.
  • "I'm truly excited to see Avi join Eco Wave Power as our COO.
  • Eco Wave Power Global ("Eco Wave Power") is a leading onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity.